Advanced Gastric Cancer
Conditions
Brief summary
The role of perioperative chemotherapy in potentially operable advanced gastric cancer (AGC) with regional lymph node metastasis is still in the area of controversy. The aim of this study is to evaluate the efficacy and toxicity of folinic acid (FA), infusional 5-fluorouracil (5-FU), and oxaliplatin (modified FOLFOX6) in potentially resectable AGC with regional lymph node (LN) metastasis.
Interventions
DRUGmFOLFOX6 (folinic acid, 5-fluorouracil, and oxaliplatin )
Modified FOLFOX6 regimen consists of oxaliplatin 100 mg/m2 and FA 100 mg/m2 given as a 2 hour intravenous infusion, followed by 5-FU 2.4 g/m2 given as a continuous infusion over 46 hour, which is repeated every 2 weeks. Patients receive 4 cycles of neoadjuvant modified FOLFOX6 followed by curative radical surgery with D2 dissection and 4 cycles of adjuvant modified FOLFOX6.
Sponsors
Seoul National University Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Previously untreated patients with pathologically proven advanced gastric adenocarcinoma with regional LN metastasis (clinical stage: cT2-4 and N+) * At least one measurable regional lymph node metastasis according to the Response Evaluation Criteria in Solid Tumors (RECIST v. 1.0) * age between 18 and 75 years * Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1 * no prior chemotherapy or radiotherapy * adequate bone marrow, hepatic and renal function (absolute neutrophil count \[ANC\] ≥ 1.5ⅹ109/L, platelet count ≥ 100ⅹ109/L, total bilirubin ≤ 1.5ⅹupper limit of normal \[ULN\], serum transaminases ≤ 2.5ⅹULN, alkaline phosphatase ≤ 2.5ⅹULN, serum creatinine ≤ 1.5ⅹULN or actual or calculated creatinine clearance ≥ 50 mL/min).
Exclusion criteria
* clinical stage T1 tumors * clinical or radiologic evidence of distant metastasis * intestinal obstruction or impending obstruction * active tumor bleeding * interstitial pneumonitis or symptomatic pulmonary fibrosis * peripheral neuropathy of National Cancer Institute Common Toxicity Criteria (NCI-CTC) grade ≥1 * pregnant or breastfeeding patients * other serious diseases
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| clinical response rate as assessed using RECIST criteria, with computed tomography (CT) scans at baseline and after 4cycles of chemotherapy | 4 cycles of chemotherapy (expected average of 8 weeks) |
Secondary
| Measure | Time frame |
|---|---|
| Time to progression | From date of study enrollment until the date of first documented progression, assessed up to 60 months |
| overall survival | From date of study enrollment until the date of first documented progression, assessed up to 60 months |
Other
| Measure | Time frame |
|---|---|
| gene expression profile | after 4 cycles of chemotherapy (expected average of 8 weeks) |
| early metabolic response by PET-CT | 2 cycles of chemotherapy (expected average of 4 weeks) |
| Pharmacologic Genetic Marker | 4 cycles of chemotherapy (expected average of 8 weeks) |
Countries
South Korea
Outcome results
None listed